Although the influence of KRAS mutation status on the immune response of patients with NSCLC remains controversial, many studies have suggested that there may be a synergistic effect between KRAS-G12C inhibitors and immunotherapy drugs combined with ICIs [58]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.